Phenome centers and global harmonization

Metabolic Phenotyping in Personalized and Public Healthcare

Volumn , Issue , 2016, Pages 291-315

  Chitayat, Seth ^a   Rudan, John F ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cancer; Chronic disease; Diabetes; Genomics; Health care; Mass spectrometry; Nuclear magnetic resonance; Phenome centers; Phenomes; Phenomics; Proteomics

Indexed keywords

EID: 84966930117     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-800344-2.00010-0     Document Type: Chapter

References (68)

1. Davis BD The isolation of biochemically deficient mutants of bacteria by means of Penicillin. Proc Natl Acad Sci USA 1949, 35(1):1-10.
2. Freimer N, Sabatti C The human phenome project. Nat Genet 2003, 34(1):15-21.
3. Gerlai R Phenomics: fiction or the future?. Trends Neurosci 2002, 25(10):506-509.
4. Schilling CH, Edwards JS, Palsson BO Toward metabolic phenomics: analysis of genomic data using flux balances. Biotechnol Prog 1999, 15(3):288-295.
5. Warringer J, Ericson E, Fernandez L, Nerman O, Blomberg A High-resolution yeast phenomics resolves different physiological features in the saline response. Proc Natl Acad Sci USA 2003, 100(26):15724-15729.
6. Zbuk KM, Eng C Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007, 7(1):35-45.
7. Newton I. Axioms or Laws of Motion. Principia 1729:19-20.
8. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL Indices of relative weight and obesity. J Chronic Dis 1972, 25(6):329-343.
9. Delneri D, Brancia FL, Oliver SG Towards a truly integrative biology through the functional genomics of yeast. Curr Opin Biotechnol 2001, 12(1):87-91.
10. Lindon JC, Nicholson JK, Holmes E, Everett JR Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magnetic Res 2000, 12:289-320.
11. Nicholson JK, Lindon JC, Holmes E Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29(11):1181-1189.
12. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol 2001, 19(1):45-50.
13. Smith LL Key challenges for toxicologists in the 21st century. Trends Pharmacol Sci 2001, 22(6):281-285.
14. Davis VW, Bathe OF, Schiller DE, Slupsky CM, Sawyer MB Metabolomics and surgical oncology: potential role for small molecule biomarkers. J Surg Oncol 2011, 103(5):451-459.
15. Di Leo A, Claudino W, Colangiuli D, Bessi S, Pestrin M, Biganzoli L New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann Oncol 2007, 18(Suppl. 12):xii8-xi14.
16. Malandrino N, Smith RJ Personalized medicine in diabetes. Clin Chem 2011, 57(2):231-240.
17. Mirnezami R, Kinross JM, Vorkas PA, Goldin R, Holmes E, Nicholson J, et al. Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Ann Surg 2012, 255(5):881-889.
18. Saving women's lives: strategies for improving breast cancer detection and diagnosis 2005, National Academies Press, Washington, DC. J.E. Joy, E.E. Penhoet, D.B. Petitti (Eds.).
19. Nicholson JK, Connelly J, Lindon JC, Holmes E Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1(2):153-161.
20. Principles of diabetes mellitus 2009, Springer, New York, NY. 2nd ed. L. Poretsky (Ed.).
21. Filler AG Neurography and diffusion tensor imaging: origins, history & clinical impact. Nat Proceedings 2009.
22. MacPherson DW, Gushulak BD, Macdonald L Health and foreign policy: influences of migration and population mobility. Bull World Health Org 2007, 85(3):200-206.
23. Warner KE Effects of the antismoking campaign: an update. Am J Public Health 1989, 79(2):141-151.
24. Naftali T, Mechulam R, Lev LB, Konikoff FM Cannabis for inflammatory bowel disease. Dig Dis 2014, 32(4):468-474.
25. Goldsmith P, Fenton H, Morris-Stiff G, Ahmad N, Fisher J, Prasad KR Metabonomics: a useful tool for the future surgeon. J Surg Res 2010, 160(1):122-132.
26. Mirnezami R, Nicholson J, Darzi A Preparing for precision medicine. N Engl J Med 2012, 366(6):489-491.
27. Reddin B The output oriented organization 1988, Gower Publishing, Aldershot, UK.
28. Strisciuglio P, Concolino D New strategies for the treatment of phenylketonuria (PKU). Metabolites 2014, 4(4):1007-1017.
29. Blau N, Shen N, Carducci C Molecular genetics and diagnosis of phenylketonuria: state of the art. Expert Rev Mol Diagn 2014, 14(6):655-671.
30. Palla R, Peyvandi F, Shapiro AD Rare bleeding disorders: diagnosis and treatment. Blood 2015, 125(13):2052-2061.
31. Touw CM, Derks TG, Bakker BM, Groen AK, Smit GP, Reijngoud DJ From genome to phenome-Simple inborn errors of metabolism as complex traits. Biochim Biophys Acta 2014, 1842(10):2021-2029.
32. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979, 76(5):2420-2424.
33. Kress M, May E, Cassingena R, May P Simian virus 40-transformed cells express new species of proteins precipitable by anti-Simian virus 40 tumor serum. J Virol 1979, 31(2):472-483.
34. Linzer DI, Levine AJ Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17(1):43-52.
35. Linzer DI, Maltzman W, Levine AJ The SV40 A gene product is required for the production of a 54,000MW cellular tumor antigen. Virology 1979, 98(2):308-318.
36. Rotter V, Witte ON, Coffman R, Baltimore D Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. J Virol 1980, 36(2):547-555.
37. Khoo KH, Verma CS, Lane DP Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014, 13(3):217-236.
38. Kruse JP, Gu W Modes of p53 regulation. Cell 2009, 137(4):609-622.
39. Meek DW, Anderson CW Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 2009, 1(6):a000950.
40. Rubinstein WS Hereditary breast cancer in Jews. Fam Cancer 2004, 3(3-4):249-257.
41. Frueh DP, Goodrich AC, Mishra SH, Nichols SR NMR methods for structural studies of large monomeric and multimeric proteins. Curr Opin Struct Biol 2013, 23(5):734-739.
42. Rosano GL, Ceccarelli EA Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 2014, 5:172.
43. 15N multidimensional NMR to study the structure and dynamics of proteins. Annu Rev Biophys Biomol Struct 1998, 27:357-406.
44. Saridakis E, Chayen NE Systematic improvement of protein crystals by determining the supersolubility curves of phase diagrams. Biophys J 2003, 84(2 Pt 1):1218-1222.
45. Tsumoto K, Ejima D, Senczuk AM, Kita Y, Arakawa T Effects of salts on protein-surface interactions: applications for column chromatography. J Pharm Sci 2007, 96(7):1677-1690.
46. Cheatham B, Kahn CR Insulin action and the insulin signaling network. Endocr Rev 1995, 16(2):117-142.
47. 1H NMR and UPLC-MS(E) statistical heterospectroscopy: characterization of drug metabolites (xenometabolome) in epidemiological studies. Anal Chem 2008, 80(18):6835-6844.
48. Maher AD, Fonville JM, Coen M, Lindon JC, Rae CD, Nicholson JK Statistical total correlation spectroscopy scaling for enhancement of metabolic information recovery in biological NMR spectra. Anal Chem 2012, 84(2):1083-1091.
49. 1H NMR spectra of biofluids: application to drug metabolite profile identification and enhanced information recovery. Anal Chem 2009, 81(15):6458-6466.
50. Gray N, Lewis MR, Plumb RS, Wilson ID, Nicholson JK High-throughput microbore UPLC-MS metabolic phenotyping of urine for large-scale epidemiology studies. J Proteome Res 2015, 14:2714-2721.
51. Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, et al. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc 2013, 8(1):17-32.
52. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 2010, 5(6):1005-1018.
53. Balog J, Sasi-Szabo L, Kinross J, Lewis MR, Muirhead LJ, Veselkov K, et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med 2013, 5(194). 194ra93.
54. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC Metabolic phenotyping in clinical and surgical environments. Nature 2012, 491(7424):384-392.
55. Morgan MW, Zamora NE, Hindmarsh MF An inconvenient truth: a sustainable healthcare system requires chronic disease prevention and management transformation. Healthc Pap 2007, 7(4):6-23.
56. Hirsch JA, Leslie-Mazwi TM, Barr RM, McGinty G, Nicola GN, Silva E, et al. The bundled payments for care improvement initiative. J Neurointerv Surg 2015.
57. Grunfeld EaE CC The interface between primary care and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr 2010, 40:25-30.
58. Rich PB, Adams SD Health care: economic impact of caring for geriatric patients. Surg Clin North Am 2015, 95(1):11-21.
59. Heidari B Rheumatoid arthritis: early diagnoses and treatment outcomes. Caspian J Int Med 2011, 2(1):161-170.
60. Raziee HR, Cardoso R, Seevaratnam R, Mahar A, Helyer L, Law C, et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer 2012, 15(Suppl. 1):S116-S124.
61. Rosenthal EL, Warram JM, Bland KI, Zinn KR The status of contemporary image-guided modalities in oncologic surgery. Ann Surg 2015, 261(1):46-55.
62. Law TT, Kwong A Surgical margins in breast conservation therapy: how much should we excise?. South Med J 2009, 102(12):1234-1237.
63. Coen M, Holmes E, Lindon JC, Nicholson JK NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008, 21(1):9-27.
64. Petrof EO, Khoruts A From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014, 146(6):1573-1582.
65. Jump RL, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, et al. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One 2014, 9(7):e101267.
66. Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014, 5:3114.
67. Soman D, N-Marandi S Managing Customer Value 2010, Wold Scientific Publishing Company, Singapore.
68. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282(15):1458-1465.